Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
Publication
, Conference
Hong, DS; Schoffski, P; Calvo, A; Sarantopoulos, J; Ochoa De Olza, M; Carvajal, RD; Prawira, A; Kyi, C; Esaki, T; Akerley, WL; De Braud, FG ...
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
3012 / 3012
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hong, D. S., Schoffski, P., Calvo, A., Sarantopoulos, J., Ochoa De Olza, M., Carvajal, R. D., … Tan, D.-W. (2018). Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. In Journal of Clinical Oncology (Vol. 36, pp. 3012–3012). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.3012
Hong, David S., Patrick Schoffski, Aitana Calvo, John Sarantopoulos, María Ochoa De Olza, Richard D. Carvajal, Amy Prawira, et al. “Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.” In Journal of Clinical Oncology, 36:3012–3012. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3012.
Hong DS, Schoffski P, Calvo A, Sarantopoulos J, Ochoa De Olza M, Carvajal RD, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3012–3012.
Hong, David S., et al. “Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 3012–3012. Crossref, doi:10.1200/jco.2018.36.15_suppl.3012.
Hong DS, Schoffski P, Calvo A, Sarantopoulos J, Ochoa De Olza M, Carvajal RD, Prawira A, Kyi C, Esaki T, Akerley WL, De Braud FG, Hui R, Zhang T, Soo RA, Maur M, Weickhardt AJ, Roy Chowdhury N, Sabatos-Peyton C, Kwak EL, Tan DS-W. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3012–3012.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
3012 / 3012
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences